Document is current
Any future updates will be listed below
-
Authors
Toh, Eric
Baryalai, Palwasha
Nadeem, Aftab https://orcid.org/0000-0002-1439-6216
Aung, Kyaw Min https://orcid.org/0000-0001-6898-0170
Chen, Sa
Persson, Karina
Persson, Jenny L.
Uhlin, Bernt Eric https://orcid.org/0000-0002-2991-8072
Wai, Sun Nyunt https://orcid.org/0000-0003-4793-4671
-
Funding
Funding for this research was provided by:
Cancerfonden (2020-711)
Cancerfonden (CAN-2017-419)
Cancerfonden (CAN-2017-381)
Cancerfonden (CAN-2017-381)
Cancerfonden (CAN-2017-419)
Cancerfonden (2020-711)
Vetenskapsrådet (No. 2018-02914)
Vetenskapsrådet (2018-02914)
Vetenskapsrådet (No. 2016-05009)
Vetenskapsrådet (2019-01318)
Vetenskapsrådet (2019-01720)
Vetenskapsrådet (2018-02914)
Stiftelsen Kempe-Carlgrenska Fonden (No. SMK-1553)
European Commission (H2020-MSCA-ITN-2018)
Kempestiftelserna (JCK-1728)
- License Information
-
More Information
Article History
Received: 1 July 2022
Revised: 24 November 2022
Accepted: 28 November 2022
First Online: 6 December 2022
Competing interests
: SNW, BEU, AN, and KP wish to make the disclosure that we are named inventors in a PCT application (<i>Vibrio cholerae</i> protein for use against cancer) published under No. WO 2021/071419A1. This does not alter our adherence to Cell Death & Disease policies on sharing data and materials.
